Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 51Small Cell Lung Carcinoma 23Breast Neoplasms 18Sarcoma 17Lung Neoplasms 10Carcinoma, Hepatocellular 10Esophageal Squamous Cell Carcinoma 9Stomach Neoplasms 8Neoplasms 8Triple Negative Breast Neoplasms 7Ovarian Neoplasms 7Nasopharyngeal Carcinoma 7Thyroid Neoplasms 6Neoplasm Metastasis 6Esophageal Neoplasms 6Pancreatic Neoplasms 5NSCLC 5Colorectal Neoplasms 5Carcinoma 5Uterine Cervical Neoplasms 4Pheochromocytoma 4Endometrial Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Ovarian Epithelial 4Recurrence 3Paraganglioma 3Non-squamous Non-small Cell Lung Cancer 3Glioma 3Fallopian Tube Neoplasms 3Cholangiocarcinoma 3

Interventions

Surgical Procedures, Operative 4Magnetic Resonance Spectroscopy 3Exenatide 3tocilizumab 2Temozolomide 2Surveys and Questionnaires 2Radiotherapy 2Proton Therapy 2Mental Status and Dementia Tests 2Donepezil 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2trifluridine tipiracil drug combination 1trametinib 1tozuleristide 1tovorafenib 1temsirolimus 1gallium Ga 68 dotatate 1entinostat 1dabrafenib 1cobimetinib 1carboxyamido-triazole 1binimetinib 1antineoplaston AS 2-1 1antineoplaston A10 1anlotinib 1Verteporfin 1Vemurafenib 1Tumor Burden 1Transurethral Resection of Bladder 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Craniopharyngioma × anlotinib × Clear all
NCT06970145 2025-11-18

Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma

Nanfang Hospital, Southern Medical University

Phase 1/2 Recruiting
57 enrolled
CNS

Craniopharyngioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡